Protokinetix Inc. has entered into a research agreement with University of British Columbia to test the effect of its Anti-Aging Glycopeptide (AAGP) on monoclonal antibody production and bone marrow recovery. Under the agreement, UBC's antibody lab will test whether AAGP enhances the production of monoclonal antibodies from cell lines, an important manufacturing issue for current immunotherapies. It will also test whether AAGP enhances the survival/efficacy of engraftment of hematopoietic stem cells, a technical hurdle in cell based therapies for bone marrow transplantation and cancer therapy. The agreement enables Protokinetix and UBC to determine whether AAGP enhances the ex vivo survival and maintenance of multipotent potential in a way that could be used to enhance bone marrow transplantation.